(Q34378757)

English

The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 August 2017

2 references

5 November 2020

7 January 2023

comparative study

1 reference

systematic review

1 reference

The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review (English)

1 reference

Europe PubMed Central

1 August 2017

diabetic retinopathy

1 reference

5 November 2020

macular retinal edema

1 reference

5 November 2020

humanized antibody

1 reference

13 December 2019

1 reference

based on heuristic

inferred from title

angiogenesis inhibitor

1 reference

5 November 2020

systematic review

1 reference

based on heuristic

inferred from title

1

object named as

John A Ford

1 reference

Europe PubMed Central

1 August 2017

object named as

Andrew Elders

2

0 references

author name string

Deepson Shyangdan

3

1 reference

Europe PubMed Central

1 August 2017

Pamela Royle

4

1 reference

Europe PubMed Central

1 August 2017

Norman Waugh

5

1 reference

Europe PubMed Central

1 August 2017

language of work or name

0 references

publication date

13 August 2012

11 references

Europe PubMed Central

1 August 2017

13 March 2019

14 March 2019

24 March 2019

25 April 2019

17 June 2019

27 September 2019

27 November 2019

13 December 2019

5 November 2020

7 January 2023

11 references

Europe PubMed Central

1 August 2017

13 March 2019

14 March 2019

24 March 2019

25 April 2019

17 June 2019

27 September 2019

27 November 2019

13 December 2019

5 November 2020

7 January 2023

345

1 reference

Europe PubMed Central

1 August 2017

e5182

1 reference

Europe PubMed Central

1 August 2017

copyright license

Creative Commons Attribution-NonCommercial

10 references

13 March 2019

14 March 2019

24 March 2019

25 April 2019

17 June 2019

27 September 2019

27 November 2019

13 December 2019

5 November 2020

7 January 2023

on focus list of Wikimedia project

0 references

Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Intravitreal ranibizumab in diabetic macular edema

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Treatment of diabetic retinopathy with anti-VEGF drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Current approaches to the management of diabetic retinopathy and diabetic macular oedema

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Meta-analysis and review on the effect of bevacizumab in diabetic macular edema

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Systematic review of intravitreal bevacizumab injection for treatment of primary diabetic macular oedema

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Use of antivascular endothelial growth factor for diabetic macular edema

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Macular perfusion determined by fundus fluorescein angiography at the 4-month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (Bolt Study): Report 1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Pattern electroretinogram changes after intravitreal bevacizumab injection for diabetic macular edema

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Changing paradigms in the treatment of diabetic retinopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Intravitreal bevacizumab for treatment of diabetic macular edema

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Management of diabetic retinopathy: a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Mechanisms of adverse effects of anti-VEGF therapy for cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Current treatment approaches in diabetic macular edema

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Indirect comparisons of competing interventions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Combination of direct and indirect evidence in mixed treatment comparisons

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Epidemiology of diabetic retinopathy and macular oedema: a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

6 July 2018

Intravitreal triamcinolone acetonide versus combined intravitreal bevacizumab and dexamethasone in diffuse diabetic macular oedema

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

27 October 2018

Off-label prescribing in macular degeneration.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

27 October 2018

Initial macular thickness and response to treatment in diabetic macular edema

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

27 October 2018

Intravitreal bevacizumab combined with/without triamcinolone acetonide in single injection for treatment of diabetic macular edema.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

27 October 2018

Analysis of the effect of intravitreal bevacizumab injection on diabetic macular edema after cataract surgery

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

27 October 2018

Prevention of vision loss after cataract surgery in diabetic macular edema with intravitreal bevacizumab: a pilot study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

27 October 2018

Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

27 October 2018

Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

27 October 2018

Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration patients treated with ranibizumab.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

27 October 2018

Use of triamcinolone and bevacizumab in 25G phaco-vitrectomy surgery for the treatment of cataract and diabetic macular edema

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

27 October 2018

A masking device and method to create custom laser exposure patterns for verteporfin photodynamic therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

27 October 2018

Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3418219

27 October 2018

Role of combined cataract surgery and intravitreal bevacizumab injection in preventing progression of diabetic retinopathy: prospective randomized study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22890029

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema

1 reference

https://pubmed.ncbi.nlm.nih.gov/22890029

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prophylactic intravitreal bevacizumab for diabetic macular edema (thickening) after cataract surgery: prospective randomized study

1 reference

https://pubmed.ncbi.nlm.nih.gov/22890029

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group

1 reference

https://pubmed.ncbi.nlm.nih.gov/22890029

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacotherapy for diabetic retinopathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22890029

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Prognostic factors for visual outcome after intravitreal drug therapy for chronic diabetic macular oedema]

1 reference

https://pubmed.ncbi.nlm.nih.gov/22890029

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vascular endothelial growth factor is a critical stimulus for diabetic macular edema

1 reference

https://pubmed.ncbi.nlm.nih.gov/22890029

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/BMJ.E5182

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34378757&oldid=1805745660"